KNP-101
/ Kanaph Therap, Dong-A
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
March 26, 2025
Overcoming systemic toxicity of IL-12-based immunotherapy by tumor-targeting and IL-12 attenuation
(AACR 2025)
- "KNP-101 exhibited a wide therapeutic window, by showing potent anti-tumor activities and significantly improved safety profiles. These attributes position KNP-101 as a promising therapeutic option for patients facing resistance to current cancer therapies."
IO biomarker • Oncology • IFNG • IL12A
October 06, 2022
Overcoming systemic toxicity of IL-12-based immunotherapy by tumor-targeting and IL-12 attenuation
(SITC 2022)
- "Our KNP-101 has a widen therapeutic window by maintaining potent anti-tumor activities and showing much improved safety profiles. We hope that KNP-101 can benefit patients in the future who suffer from primary and acquired resistance of the current anti-PD-1/PD-L1 treatments."
IO biomarker • Oncology • IFNG • IL12A
1 to 2
Of
2
Go to page
1